PD1ACR-T cells

**PD1ACR-T cells** are a form of engineered T cell therapy designed for cancer immunotherapy. These cells are genetically modified T lymphocytes expressing an artificial chimeric antigen receptor (ACR) that targets the PD-1/PD-L1 immune checkpoint axis. The PD1ACR construct enables the T cells to specifically recognize and bind to PD-L1 overexpressed on tumor cells, leading to targeted killing of cancer cells. In preclinical studies, PD1ACR-T cells demonstrated significant antitumor activity in mouse models of pancreatic cancer, efficiently eliminating PD-L1-positive tumor cells and suppressing tumor growth, with increased survival compared to control groups[2]. The primary mechanism involves both recognition of PD-L1 and blockade of checkpoint signaling, enhancing T cell activation and antitumor response. Compared to conventional checkpoint blockade therapies, this modality provides direct tumor targeting and may reduce systemic immune-related adverse events by localizing activity to the tumor microenvironment[2]. Development and validation have included in vitro cytotoxicity assays and multiple mouse tumor models.

Other names

PD1ACR-T cellsPD-1ACR-T cellsPD 1ACR-T cells